Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
See a half-lit moon shine among the stars of Aquarius on Nov. 27 - 2Munich Security Conference chief defends inviting AfD lawmakers
- 3Investigate the Excellence of Professional flowerbeds: A Virtual Local escort
- 410 Hints for an Effective New employee screening
- 5Japan deploys the military to counter a surge in bear attacks
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Vote In favor of Your Favored Kind Of Bites
- The Ascent of Rousing Pioneers Who Formed History
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- 4 astronauts are now on their path to the moon. Here’s what happens next
- Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
